数据链接：
官方服务：
资源简介：
Combination assays of RAD001 and AEW541 / AEE788.
应用场景：
创建时间：
2017-06-08
相关数据集
An observational study of apatinib combined with XELOX regimen in postoperative adjuvant therapy of colorectal cancer
Interventions: experimental group:Apatinib combined with oxaliplatin and capecitabine (XELOX) g Primary outcome(s): Disease free survival Study Design: Single arm
NIAID Data Ecosystem80
Median progression-free survival by lines of treatment.
Median progression-free survival by lines of treatment.
NIAID Data Ecosystem40
Median overall survival and progression-free survival hazard ratios (HRs) and 95% Credible Intervals for cabazitaxel, abiraterone and enzalutamide using Bayesian fixed effects modeling.
Median overall survival and progression-free survival hazard ratios (HRs) and 95% Credible Intervals for cabazitaxel, abiraterone and enzalutamide using Bayesian fixed effects modeling.
NIAID Data Ecosystem20
DMAMCL inhibition of intracranial C6 tumor growth.
Note: DMA-25, DMA-50, and DMA-100 represent DMAMCL at doses of 25, 50, and 100 mg/kg, respectively. Inhibition represents the percent decrease in tumor weight compared to the vehicle group. *p < 0.05,
NIAID Data Ecosystem50
Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)
PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work compared to main
NIAID Data Ecosystem40
